Clinical Study
Efficacy and Safety of Ropivacaine Addition to Intrathecal Morphine for Pain Management in Intractable Cancer
Table 1
Demographics and clinical data
.
| | Morphine alone | Morphine + ropivacaine |
| Age (years) | 64.0 ± 13.4 | 62.6 ± 9.92 | Sex (male/female) | 11/8 | 14/3 | Cancer type () | | | Bladder | 2 | 1 | Bile duct | 1 | 0 | Colon | 2 | 1 | Duodenum | 1 | 1 | Esophagus | 1 | 2 | Kidney | 0 | 1 | Liver | 1 | 2 | Lung | 3 | 4 | Pancreas | 1 | 0 | Penis | 1 | 0 | Sarcoma | 1 | 0 | Stomach | 2 | 3 | Ureter | 2 | 1 | Uterus | 1 | 1 | Location of pain () | | | Chest | 2 | 3 | Abdomen | 7 | 6 | Lower limb Preoperative systemic opioid type () | 10 | 8 | Morphine | 4 | 2 | Oxycodone | 10 | 11 | Fentanyl | 5 | 4 |
|
|
Data from 36 patients.
|